S. Schmatloch

发表

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

P. Fasching, T. Fehm, S. Loibl, 2011, British Journal of Cancer.

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

C. Denkert, W. Eiermann, F. Marmé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Michael Gnant, Jonas Bergh, Richard Greil, 2016, JAMA.

Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis

T. Fehm, T. Kühn, S. Loibl, 2020, Geburtshilfe und Frauenheilkunde.

Abstract P1-13-05: GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses

A. Schneeweiss, S. Loibl, N. Burchardi, 2016 .

Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

E. Inwald, J. Blohmer, W. Friedmann, 2022, Journal of Cancer Research and Clinical Oncology.

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European journal of cancer.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

A. Schneeweiss, P. Neven, S. Loibl, 2021, European journal of cancer.

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of Clinical Oncology.

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, The Lancet. Oncology.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

T. Fehm, I. Bauerfeind, M. Untch, 2013, The Lancet. Oncology.

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

A. Schneeweiss, C. Denkert, S. Loibl, 2017, Breast Cancer Research and Treatment.

Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.

F. Marmé, S. Loibl, M. Untch, 2021, JAMA oncology.

Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

E. Inwald, J. Blohmer, W. Friedmann, 2022, Journal of Cancer Research and Clinical Oncology.

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.

P. Fasching, W. Weichert, C. Denkert, 2019, European journal of cancer.

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

A. Schneeweiss, C. Denkert, S. Loibl, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial

P. Fasching, A. Schneeweiss, C. Denkert, 2020 .

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

T. Fehm, J. Heil, T. Kühn, 2017, Breast.

A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.

P. Fasching, A. Schneeweiss, C. Denkert, 2016 .

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

P. Fasching, A. Schneeweiss, C. Denkert, 2018 .

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

F. Marmé, S. Linn, K. Weber, 2017, Breast Cancer Research and Treatment.

Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients.

F. Marmé, S. Loibl, V. Nekljudova, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD7-10: Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

F. Marmé, S. Loibl, V. Nekljudova, 2018 .

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

C. Denkert, F. Marmé, S. Loibl, 2021 .

Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)

Marcus Schmidt, S. Kümmel, S. Schmatloch, 2021, Anticancer Research.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

P. Fasching, C. Denkert, F. Marmé, 2021, BMC Cancer.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

P. Fasching, C. Denkert, F. Marmé, 2021, BMC cancer.

215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer

M. Piccart, M. Gnant, A. DeMichele, 2017 .

264PDGAIN2: ADJUVANT PHASE III TRIAL COMPARING AN INTENSIFIED DOSE-DENSE ADJUVANT THERAPY WITH ENPC COMPARED WITH A DOSE-DENSE, DOSE-ADAPTED THERAPY WITH DTEC DTDOCETAXEL IN PATIENTS WITH PRIMARY BREAST CANCER AND A HIGH RISK OF RECURRENCE.

A. Schneeweiss, S. Loibl, N. Burchardi, 2014, Annals of Oncology.

Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE Randomized Clinical Trial

M. Untch, V. Nekljudova, J. Huober, 2023, European Journal of Cancer.

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

A. Schneeweiss, J. Budczies, F. Marmé, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

R. Greil, J. Bergh, P. Malmström, 2016, JAMA.

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

A. Schneeweiss, C. Denkert, F. Marmé, 2021, European journal of cancer.

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

T. Fehm, J. Heil, T. Kühn, 2017, Breast.

Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)

T. Fehm, S. Loibl, I. Bauerfeind, 2018, Clinical & Experimental Metastasis.